#CMOncologyNews?is a biweekly newsletter that focuses on the latest developments in the field of oncology. The newsletter provides updates on clinical trials, new treatments, and emerging technologies in cancer care. It is designed for oncologists, researchers, and healthcare professionals who want to stay up-to-date with the latest trends and insights in oncology.
-
Initial Therapeutics
have raised $75 million in their Series A funding. Initial developed its proprietary STOPS platform to discover new therapeutics based on the recently demonstrated scientific premise that translation of a specific protein can be selectively interrupted at the moment in which its linear sequence is first produced in the exit tunnel of the ribosome.
-
Vedanta Biosciences, Inc.
have raised $106.5 million to fund their Phase 3 trial for lead candidate, VE303. The VE303 study would be the first pivotal phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta Biosciences is pioneering as a next-generation approach to?microbiome therapy.
-
Orbital Therapeutics
have raised a huge $270 million in their Series A financing. Orbital aims to expand the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement.
-
Sanofi
and
Flatiron Health
have partnered to re-tool clinical trials focused on cancer treatments by leveraging more efficient transfers of data.
-
Carina Biotech
will be showcasing its planned Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 in patients with metastatic colorectal cancer (mCRC) at the 2023 American Society of Clinical Oncology in June.
-
CG Oncology
have announced new Phase 2 data clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck’s anti-PD-1 therapy KEYTRUDA? (pembrolizumab) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
- Senior Director of Medicinal Chemistry - West Coast
- Principal Scientist (Medicinal Chemistry) - Boston
- Director of Nonclinical Development - West Coast
- Director of mRNA - Bay Area
- Head of In Vivo Pharmacology - Boston
Do you have any thoughts, or news to share? Join the conversation on LinkedIn by following the hashtag?#CMOncologyNews.
If you're looking to add exceptional talent to your team or seeking new opportunities in the industry, please feel free to reach out to me. As a head-hunter specializing in the Oncology industry, I partner with leading drug discovery companies to help them attract and retain top talent globally. Drop me a message and let's catch up.
